Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million. This news came after 23andMe filed for bankruptcy in March 2025. The sale covers most of 23andMe’s assets but not its Lemonaid Health unit, which will shut down.
A U.S. Bankruptcy Court needs to approve the deal at a hearing on June 17, 2025. If everything goes through, the sale will finish in the third quarter of 2025.
Transaction Details
The deal leaves out Lemonaid Health, a telemedicine service 23andMe picked up in 2021. That part of the business will close as 23andMe wraps up its bankruptcy. To help with the process, 23andMe got $35 million in financing from JMB Capital Partners.
Regeneron’s Strategic Rationale
Regeneron, a big name in biotechnology, wants 23andMe’s genetic data. This data comes from 15 million people who used 23andMe’s DNA testing kits. The company plans to use it at its Regeneron Genetics Center to study diseases and create new treatments.
Dr. George D. Yancopoulos, Regeneron’s Chief Scientific Officer, said, “We know how to protect genetic data. We’ll keep 23andMe’s customers’ information safe.” This promise matters because 23andMe had a data breach in 2023 that upset many users.
Privacy Concerns and Protections
Privacy is a key issue here. 23andMe’s huge database could be a goldmine for research, but people worry about who controls their DNA info. Regeneron says it will stick to 23andMe’s privacy rules and keep data secure. A court-appointed Consumer Privacy Ombudsman will check the sale and report back by June 10, 2025, to make sure everything is fair.
Market Reaction
The market liked the news—Regeneron’s stock went up to $589.27 on May 19, 2025, a small jump of 0.66%. Analysts think the stock could climb to $805.26, a 35.49% increase.
Public Sentiment
People online have different views. Some fear more privacy risks. Others think it’s good for health research. One X user wrote, “Regeneron snags 23andMe for $256M in bankruptcy. From $6B to this—a warning about trusting companies with your data.”
This sale fits a bigger pattern in health care. Companies want genetic data to build better medicines. Regeneron’s purchase shows how much that info is worth. But it also makes people ask: how do we keep personal data safe while using it for science?
In the end, Regeneron’s $256 million deal for 23andMe could change health research. It gives Regeneron a big pool of genetic info to work with. For 23andMe, it’s the end of a tough road. The court still has to say yes, but if it does, this could shape how genetic data helps science—and how we protect it.
